The Non-Malignant Channel is supported with funding from Agios (Gold).
The Sickle Cell Disease Channel is supported with funding from Agios (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCAT 2024 | The priorities when treating SCD in SSA
Leon Tshilolo, MD, PhD, Centre Hospitalier Monkole, Kinshasa, DR Congo, comments on the priorities when treating patients with sickle cell disease (SCD) in sub-Saharan Africa (SSA). An accurate diagnosis in infancy or early childhood is needed to ensure the implementation of prophylactic measures to reduce the risk of malaria and severe infections, improving patient outcomes. Prof. Tshilolo highlights that these measures are readily accessible to patients, even in rural locations or areas without highly trained healthcare professionals. This interview took place at the 19th Annual Scientific Conference of the Academy for Sickle Cell and Thalassaemia (ASCAT 2024) in London, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Novo Nordisk, Pfizer.
